Relevant Market Insights India’s biopharmaceutical sector is at a pivotal point in its evolution. Long celebrated as the world’s “pharmacy of the world” for generics and vaccines, the broader bi...
Recent Regulatory Developments India’s biopharmaceutical industry stands at an inflection point where its scientific capabilities and production scale are increasingly recognized globa...
In recent years, India’s pharmaceutical landscape has witnessed a significant transformation. Beyond being the “pharmacy of the world” for affordable medicines, India is emerging as a preferred global...
Relevant Global and Market Data India’s biopharmaceutical export story is one of remarkable transformation. From being a net importer of medicines in the late 20th century to becoming the “...
Latest Developments on API Self-Reliance India has long been recognized as the “pharmacy of the world,” supplying affordable generic medicines to countries across the globe. However, despite its...
Key Highlights: Implications: Semaglutide generics could slash Novo Nordisk pricing by 70-80% in India’s $2.5B diabetes market (12% CAGR), capturing 25%+ share and pressuring chronic...
Key Highlights: Implications: Lilly’s India manufacturing bet locks in low-cost production muscle, outflanking China-dependent rivals as Mounjaro mania drives capacit...
Key Highlights: Implications: India’s GATINN catapults Servier into SPC dominance, crushing fragmented chronic therapy rivals while exploding patient compliance across emerging marke...
Relevant Industry Developments India’s biopharmaceutical sector is no longer defined solely by its global dominance in generics. Over the past decade, biologics and biosimilars have emerged as o...
